Suppr超能文献

开发代谢综合征疗法:挑战、机遇和……未知。

Developing therapies for the metabolic syndrome: challenges, opportunities, and… the unknown.

出版信息

Ther Adv Endocrinol Metab. 2010 Apr;1(2):89-94. doi: 10.1177/2042018810375812.

Abstract

Metabolic syndrome refers to a clustering of established and emerging cardiovascular disease risk factors within a single individual. The established risk factors, such as obesity, diabetes, dyslipidaemia and hypertension, and other emerging risk factors are closely related to central obesity (especially intra-abdominal adiposity) and insulin resistance. However, debate continues about the very existence of the metabolic syndrome. Despite the controversies, many existing and new therapies are targeting the metabolic syndrome and component risk factors. To date, no therapies have been approved specifically for treating the metabolic syndrome. In this article some of the challenges and opportunities in developing therapies for the metabolic syndrome are discussed.

摘要

代谢综合征是指个体中存在多种已确立和新兴的心血管疾病危险因素。这些已确立的危险因素,如肥胖、糖尿病、血脂异常和高血压,以及其他新兴的危险因素,与中心性肥胖(尤其是内脏型肥胖)和胰岛素抵抗密切相关。然而,代谢综合征的存在仍然存在争议。尽管存在争议,但许多现有的和新的治疗方法都针对代谢综合征及其组成的危险因素。迄今为止,尚无专门用于治疗代谢综合征的疗法获得批准。本文讨论了开发代谢综合征治疗方法所面临的一些挑战和机遇。

相似文献

1
Developing therapies for the metabolic syndrome: challenges, opportunities, and… the unknown.
Ther Adv Endocrinol Metab. 2010 Apr;1(2):89-94. doi: 10.1177/2042018810375812.
2
Challenges in developing drugs for the metabolic syndrome.
Curr Diab Rep. 2008 Feb;8(1):31-6. doi: 10.1007/s11892-008-0007-0.
3
[From the metabolic syndrome to the concept of global cardiometabolic risk].
Orv Hetil. 2009 May 3;150(18):821-9. doi: 10.1556/OH.2009.28606.
4
The link between abdominal obesity, metabolic syndrome and cardiovascular disease.
Nutr Metab Cardiovasc Dis. 2007 May;17(4):319-26. doi: 10.1016/j.numecd.2006.07.005. Epub 2006 Nov 15.
5
Challenges associated with metabolic syndrome.
Pharmacotherapy. 2006 Dec;26(12 Pt 2):209S-217S. doi: 10.1592/phco.26.12part2.209S.
6
The metabolic syndrome - an ongoing story.
J Physiol Pharmacol. 2009 Dec;60 Suppl 7:19-24.
7
Metabolic syndrome and obesity in peritoneal dialysis.
Kidney Res Clin Pract. 2016 Mar;35(1):10-4. doi: 10.1016/j.krcp.2015.12.007. Epub 2016 Jan 13.
9
Biological specificity of visceral adipose tissue and therapeutic intervention.
Arch Physiol Biochem. 2008 Oct;114(4):277-86. doi: 10.1080/13813450802334752.
10
Metabolic syndrome and cardiovascular disease.
Ann Clin Biochem. 2007 May;44(Pt 3):232-63. doi: 10.1258/000456307780480963.

引用本文的文献

本文引用的文献

1
The metabolic syndrome: what's in a name?
Ther Adv Endocrinol Metab. 2010 Apr;1(2):39-45. doi: 10.1177/2042018810374290.
2
Advances in the treatment of prediabetes.
Ther Adv Endocrinol Metab. 2010 Feb;1(1):5-14. doi: 10.1177/2042018810366429.
3
The genetics of obesity and the metabolic syndrome.
Endocr Metab Immune Disord Drug Targets. 2010 Jun;10(2):86-108. doi: 10.2174/187153010791213100.
5
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.
Lancet. 2010 Feb 27;375(9716):735-42. doi: 10.1016/S0140-6736(09)61965-6. Epub 2010 Feb 16.
6
Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy.
N Engl J Med. 2010 Mar 4;362(9):774-7. doi: 10.1056/NEJMp1001578. Epub 2010 Feb 17.
7
The rise and fall of rosiglitazone.
Eur Heart J. 2010 Apr;31(7):773-6. doi: 10.1093/eurheartj/ehq016. Epub 2010 Feb 12.
8
Withdrawal of sibutramine in Europe.
BMJ. 2010 Feb 9;340:c824. doi: 10.1136/bmj.c824.
9
Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders.
Br J Clin Pharmacol. 2009 Dec;68(6):861-74. doi: 10.1111/j.1365-2125.2009.03549.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验